Post-marketing trials involve fewer patients than Phase III studies.

Post-marketing trials involve fewer patients than Phase III studies.

• A. True
• B. False
• C. Not sure
• D. Depends on case

Answer: (B)

In drug development, Phase III trials are designed to firmly establish efficacy and safety in a sizable, controlled population with predefined endpoints and statistical power. Post-marketing studies (Phase IV) come after approval and aim to monitor long-term safety and real-world effectiveness. Because Phase IV often seeks to detect rare or long-term adverse events and assess performance in a broad, real-world setting, these studies can enroll far more patients than a typical Phase III trial. The number of participants in post-marketing research varies by study design and regulatory needs, but it is not inherently smaller than Phase III. Some Phase IV studies are large-scale and long-term, while others are smaller or highly targeted. So the statement that post-marketing trials involve fewer patients than Phase III is not generally true.

In drug development, Phase III trials are designed to firmly establish efficacy and safety in a sizable, controlled population with predefined endpoints and statistical power. Post-marketing studies (Phase IV) come after approval and aim to monitor long-term safety and real-world effectiveness. Because Phase IV often seeks to detect rare or long-term adverse events and assess performance in a broad, real-world setting, these studies can enroll far more patients than a typical Phase III trial. The number of participants in post-marketing research varies by study design and regulatory needs, but it is not inherently smaller than Phase III. Some Phase IV studies are large-scale and long-term, while others are smaller or highly targeted. So the statement that post-marketing trials involve fewer patients than Phase III is not generally true.